VJOncology is committed to improving our service to you

ESMO 2019 | TROPHY-U-01: Initial findings

VJOncology is committed to improving our service to you

Scott Tagawa

Scott Tagawa, MD, MS, Weill Cornell Medicine, New York, NY, discusses the initial results from the TROPHY-U-01 phase II trial, assessing the efficacy and toxicities in the first cohort of patients (those who have already received platinum-based chemotherapy and immune checkpoint based therapy) with sacituzumab govitecan. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter